WIRED commissioned independent laboratory testing of peptide products purchased from New York City bodegas and found that vials labeled as containing BPC-157 contained no detectable active ingredient. According to the investigation, testing of each substance found that none contained the active ingredients listed on their labels.
The products were labeled “for research use only,” a designation that companies use in an attempt to shield themselves from legal liability. The findings add to longstanding regulatory concerns about the consumer peptide market.
Peptides also require refrigeration and are sensitive to temperature changes, meaning improper storage at retail locations could degrade any active ingredients before a consumer ever purchases them.
What happened
WIRED purchased peptide products from New York City bodegas and sent them to an independent laboratory for testing. Vials labeled as containing BPC-157 contained no detectable active ingredient. None of the tested products matched the active ingredients listed on their labels.
The products carried “for research use only” designations. This labeling strategy is used by companies selling peptide products, marketed with disclaimers suggesting they are not intended for human consumption, even when sold in retail settings accessible to the general public.
Why it matters
The independent testing confirms widespread quality and labeling problems in the consumer peptide market. The findings validate FDA warnings that “research use only” labels do not guarantee product contents, sterility, or safety.
Consumers purchasing peptides from retail locations or online cannot rely on label claims, according to the investigation’s findings. The results have implications across the peptide supply chain, affecting peptide consumers, telehealth platforms, compounding pharmacies, regulators, and retail peptide sellers.
The storage issue compounds the problem. Because peptides require refrigeration and are sensitive to temperature changes, improper storage at retail locations could further degrade active ingredients.
What to watch next
- Whether regulators take enforcement action against retail sellers of mislabeled peptide products
- How telehealth platforms and compounding pharmacies respond to consumer concerns about product integrity
- Whether additional independent testing of consumer peptide products is commissioned
- How the “research use only” labeling strategy holds up under regulatory scrutiny
Sources
Industry information only. Not medical or legal advice.
